What do domain transporter and catechol-o-methyltransferase tell us about attention deficit-hyperactivity disorder? Pharmacogenomic implications

Australian and New Zealand Journal of Psychiatry

Volumn 41, Issue 1, 2007, Pages 10-16

  Levy, Florence ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

ADHD; COMT; DAT 1; Genes; Pharmacogenomic

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE TRANSPORTER; METHIONINE; PSYCHOSTIMULANT AGENT; VALINE; CENTRAL STIMULANT AGENT; SLC6A3 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ATTENTION DEFICIT DISORDER; COGNITION; CORPUS STRIATUM; DOPAMINE BLOOD LEVEL; DRUG MEGADOSE; DRUG RESPONSE; GENE FUNCTION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; IMPULSIVENESS; LOW DRUG DOSE; PHARMACOGENOMICS; PREFRONTAL CORTEX; PSYCHOLOGIC TEST; REVIEW; SHORT TERM MEMORY; TASK PERFORMANCE; THEORETICAL MODEL; WORKING MEMORY; DOSE RESPONSE; GENETICS; METHODOLOGY; PHARMACOGENETICS;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CATECHOL O-METHYLTRANSFERASE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACOGENETICS;

EID: 34247499162     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670601050432     Document Type: Review

References (34)

1. Barkley, RA. (1997) ADHD and the nature of self-control, Guilford Press, New York
2. Sonuga-Barke, EJS. (2003) The dual pathway model of AD/HD: An elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev, 27, pp. 593-604.
3. Sagvolden, T., Johansen, EB, Aase, H. and Russell, VA. (2005) A dynamic developmental theory of attention deficit hyperactivity disorder (ADHD) predominantly hyperactive/impulsive subtype. Behav Brain Sci, 28, pp. 397-468.
4. Hay, DA, McStephen, M. and Levy, F. (2001) The developmental genetics of ADHD. Attention genes and ADHD, pp. 66-68. Brunner-Routledge, Philadelphia, PA
5. Faraone, SV, Perlis, RH and Doyle, AE (2005) Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry, 57, pp. 1313-1323.
6. Kirley, A., Hawi, Z. and Daly, G. (2002) Dopaminergic system genes in ADHD: Toward a biological hypothesis. Neuropsychopharmacology, 27, pp. 607-619.
7. Volkow, ND, Wang, G-J and Fowler, JS (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci, 21
8. Cook, EH, Stein, MA and Krasowski, MD (1995) Association of attention deficit disorder and the dopamine transporter gene. Am J Hum Genet, 56, pp. 993-998.
9. Curran, S., Mill, J. and Tahir, E. (2001) Association study of a dopamine transporter polymorphism and attention deficit hyperactivity disorder in UK and Turkish samples. Mol Psychiatry, 6, pp. 425-428.
10. Bilder, RM, Volavka, J., Lachman, HM and Grace, AA. (2004) The catechol-o-methyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology, 29, pp. 1943-1961.
11. McGough, JJ. (2005) Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry, 57, pp. 1367-1373.
12. Winsberg, BG and Comings, DE. (1999) Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry, 38, pp. 1474-1477.
13. Roman, T., Szobot, C., Martine, S., Biederman, J., Rohde, LA and Hutz, MH. (2002) Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics, 12, pp. 497-499.
14. Seamans, JK and Yang, CR. (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol, 74, pp. 1-57.
15. Kirley, A., Lowe, N. and Hawi, A. (2003) Association of the 480 bp DAT1 with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet, 121, pp. 50-54.
16. Hamarman, S., Fossella, J., Ulger, C., Brimacombe, M. and Dermody, J. (2004) Dopamine receptor4 (DRD4) 7 repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol, 14, pp. 564-574.
17. Madras, BK, Miller, GM and Fischman, AJ. (2005) The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry, 57, pp. 1397-1409.
18. Eisenberg, J., Mei-Tal, G. and Steinberg, A. (1999) Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): Association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. Am J Med Genet, 88, pp. 497-502.
19. Barr, CL, Wigg, K. and Malone, M. (1999) Linkage study of catechol-O-methyltransferase and attention-deficit hyperactivity disorder. Am J Med Genet, 88, pp. 710-713.
20. Hawi, Z., Millar, N., Daly, G., Fitzgerald, M. and Gill, M. (2000) No association between catechol-O-methyltransferase (COMT) gene polymorphism and ADHD in an Irish sample. Am J Med Genet, 96, pp. 241-243.
21. Manor, I., Kotler, M. and Sever, Y. (2000) Failure to replicate an association between the catechol-O-methyltransferase polymorphism and attention deficit hyperactivity disorder in a second, independently recruited Israeli cohort. Am J Med Genet, 96, pp. 858-860.
22. Payton, A., Holmes, J. and Barrett, JH (2001) Examining for association between candidate gene polymorphisms in the dopamine pathway and attention-deficit hyperactivity disorder: A family-based study. Am J Med Genet, 105, pp. 464-470.
23. Tahir, E., Curran, S., Yazgan, Y., Ozbay, F., Cirakoglu, B. and Asherson, P. (2000) No association between low and high activity catecholamine-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol Psychiatry, 5, pp. 396-404.
24. Qian, Q., Wang, Y. and Zhou, R. (2003) Family-based and case-control association studies of catechol-O-methyltransferase in attention deficit hyperactivity disorder suggest genetic sexual dimorphism. Am J Med Genet, 118, pp. 103-109.
25. Taerk, E., Grizenko, N. and Amor, L Ben (2004) Catechol-O-methyltransferase (COMT) Val108/158 Met polymorphism does not modulate executive function in children with ADHD. BMC Med Genet, 5, p. 30.
26. Diamond, A., Briand, L., Fossella, J. and Gehlbach, L. (2004) Genetic and neurochemical modulation of prefrontal cognitive functions in children. Am J Psychiatry, 161, pp. 125-132.
27. Mattay, VS, Goldberg, TE and Fera, F. (2003) Catechol O-methyltransferase val 158-met genotype and individual variation in brain response to amphetamine. Proc Natl Acad Sci USA, 100, pp. 6186-6191.
28. Meyer-Lindenberg, A., Kohn, PD and Kolachana, B. (2005) Midbrain dopamine and prefrontal function in humans: Interaction and modulation by COMT genotype. Nat Neurosci, 8, pp. 594-596.
29. Sprague, RL and Sleator, EK. (1997) Methylphenidate in hyperkinetic children: Differences in dose effects on learning and social behavior. Science, 198, pp. 1274-1276.
30. Evans, SW and Pelham, WE. (1991) Psychostimulant effects on academic and behavioral measures for ADHD junior high school students in a lecture format classroom. J Abnorm Child Psychol, 19, pp. 537-552.
31. Douglas, VI, Barr, RG, Desilets, J. and Sherman, E. (1994) Do high doses of stimulants impair flexible thinking in Attention-Deficit Hyperactivity Disorder?. J Am Acad Child Adolesc Psychiatry, 34, pp. 877-885.
32. Solanto, MV and Wender, EH. (1989) Neuropharmacological basis of stimulant drug action in attention deficit disorder with hyperactivity. Psychol Bull, 26, pp. 897-902.
33. Tannock, R. and Schachar, R. (1992) Methylphenidate and cognitive perseveration in hyperactive children. J Child Psychol Psychiatry Allied Disc, 33, pp. 217-228.
34. Floresco, SB, West, AR, Ash, B., Moore, H. and Grace, AA. (2004) Extrasynaptic dopamine and phasic neuronal activity. Nat Neurosci, 7, p. 199.